Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 12 04:00PM ET
0.5286
Dollar change
-0.0279
Percentage change
-5.01
%
Index- P/E- EPS (ttm)-1.71 Insider Own32.53% Shs Outstand38.27M Perf Week-6.11%
Market Cap20.23M Forward P/E- EPS next Y-1.07 Insider Trans0.00% Shs Float25.82M Perf Month-17.64%
Income-65.08M PEG- EPS next Q-0.37 Inst Own21.95% Short Float0.47% Perf Quarter-13.16%
Sales9.78M P/S2.07 EPS this Y15.48% Inst Trans-28.93% Short Ratio0.84 Perf Half Y-31.28%
Book/sh1.88 P/B0.28 EPS next Y30.60% ROA-45.72% Short Interest0.12M Perf Year-46.46%
Cash/sh1.43 P/C0.37 EPS next 5Y- ROE-64.99% 52W Range0.54 - 1.56 Perf YTD-52.80%
Dividend Est.- P/FCF- EPS past 5Y-40.84% ROI-74.48% 52W High-66.12% Beta0.93
Dividend TTM- Quick Ratio3.16 Sales past 5Y169.01% Gross Margin81.06% 52W Low-2.11% ATR (14)0.04
Dividend Ex-Date- Current Ratio3.16 EPS Y/Y TTM9.64% Oper. Margin-739.68% RSI (14)32.80 Volatility5.98% 6.84%
Employees100 Debt/Eq0.25 Sales Y/Y TTM35.86% Profit Margin-665.56% Recom3.00 Target Price1.75
Option/ShortNo / Yes LT Debt/Eq0.21 EPS Q/Q7.57% Payout- Rel Volume2.21 Prev Close0.56
Sales Surprise-8.76% EPS Surprise-17.65% Sales Q/Q-54.87% EarningsNov 12 AMC Avg Volume144.21K Price0.53
SMA20-9.89% SMA50-15.15% SMA200-35.57% Trades Volume317,997 Change-5.01%
Date Action Analyst Rating Change Price Target Change
Jan-06-22Downgrade Morgan Stanley Overweight → Equal-Weight
Mar-02-21Initiated SVB Leerink Outperform $36
Mar-02-21Initiated Stifel Buy $40
Mar-02-21Initiated Morgan Stanley Overweight $45
Mar-02-21Initiated Guggenheim Buy $42
Nov-12-24 05:35PM
04:27PM
04:05PM
Nov-07-24 10:00AM
Sep-04-24 04:05PM
07:00AM Loading…
Aug-28-24 07:00AM
Aug-13-24 04:05PM
May-24-24 06:13AM
May-15-24 03:00PM
01:34PM
08:05AM
07:29AM
May-14-24 10:54PM
04:05PM
Mar-21-24 10:53PM
04:05PM Loading…
04:05PM
Feb-27-24 07:00AM
Dec-21-23 07:30AM
Dec-05-23 07:00AM
Nov-09-23 04:05PM
Nov-07-23 07:00AM
Oct-24-23 12:30PM
Oct-23-23 10:30AM
Oct-18-23 07:00AM
Oct-17-23 07:00AM
Oct-16-23 07:00AM
Sep-28-23 07:00AM
Sep-12-23 08:05AM
Sep-05-23 04:15PM
Aug-09-23 06:10AM
04:10PM Loading…
Aug-07-23 04:10PM
Aug-03-23 07:30AM
Jul-31-23 05:27PM
Jun-13-23 11:22AM
May-30-23 08:00AM
May-25-23 05:05PM
May-11-23 04:05PM
Apr-26-23 10:00AM
Apr-11-23 07:41AM
Mar-30-23 01:16PM
Mar-29-23 04:15PM
04:05PM
Mar-14-23 04:30PM
Feb-28-23 08:00AM
Feb-01-23 08:00AM
Jan-04-23 09:31AM
Dec-14-22 04:43PM
Nov-10-22 04:05PM
Nov-07-22 08:00AM
Nov-02-22 07:20AM
Nov-01-22 10:01AM
08:00AM
Sep-09-22 12:08PM
Aug-31-22 07:30AM
Aug-25-22 12:23PM
12:02PM
Aug-10-22 04:05PM
Jul-22-22 08:44AM
Jun-10-22 07:21AM
May-27-22 08:00AM
May-26-22 06:52AM
May-13-22 08:28AM
May-12-22 04:05PM
May-11-22 07:32AM
Apr-07-22 08:00AM
Mar-30-22 04:05PM
Mar-08-22 04:30PM
Feb-12-22 06:30AM
Feb-02-22 08:00AM
Jan-27-22 01:43PM
Jan-06-22 08:00AM
Dec-17-21 06:14AM
Dec-16-21 08:00AM
Dec-06-21 04:29PM
09:23AM
06:00AM
Dec-02-21 06:00AM
Nov-19-21 08:00AM
Nov-12-21 07:00AM
Nov-09-21 04:05AM
Nov-08-21 08:00AM
Nov-03-21 08:00AM
Oct-01-21 08:00AM
Sep-08-21 07:30AM
Sep-02-21 08:00AM
Aug-27-21 05:55AM
Aug-26-21 04:05PM
Aug-16-21 06:26AM
Aug-12-21 04:05PM
Aug-02-21 04:32PM
Jul-20-21 12:42AM
Jun-22-21 08:16PM
08:00PM
06:20PM
05:33PM
03:41PM
02:10PM
01:03PM
12:30PM
12:11PM
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Its pipeline includes BDC-1001, a HER2-targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. The company was founded by Edgar G. Engleman on January 22, 2015 and is headquartered in Redwood City, CA.